Generate Biomedicines Inc.

GENB | NASDAQ

Price Alert Chart Builder DCF Calculator

$14.46

-$1.31 (-8.31%)

At close: Oct 30, 2026, 4:00 PM ET

$14.45

-$0.01 (-0.07%)

Pre-market: Nov 2, 2026, 7:37 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $1.86B

Enterprise Value $1.46B

Beta -0.14

Average Volume 1.08M

Shares Outstanding (Diluted) 128.24M

Shares Change YoY N/A

Institutional Ownership 78.19%

Exchange NASDAQ

ISIN US3709201004

Price Performance

Price Change 1M -3.7%

Price Change 3M 3.3%

Price Change 6M 10.0%

Price Change YTD N/A

Price Change 1Y N/A

Price Change 3Y N/A

Price Change 5Y N/A

1M CAGR (ann.) -15.6%

1Y CAGR (ann.) N/A

5Y CAGR (ann.) N/A

All-Time CAGR 22.1%

Valuation

PE Ratio -13.64

Forward PE N/A

PEG Ratio -0.09

Forward PEG 0.12

PS Ratio 137.09

Forward PS 77.90

PB Ratio 4.07

P/FCF Ratio -12.97

P/Adj. FCF Ratio -12.27

P/OCF Ratio -9.90

EV/Sales 107.93

EV/EBIT -11.14

EV/EBITDA -11.72

EV/FCF -10.21

Earnings Yield -7.3%

FCF Yield -7.7%

Adj. FCF Yield -8.2%

Financial Health

Net Cash $457.42M

Total Debt $62.63M

Cash & Short-Term Investments $457.42M

Total Assets $561.69M

Current Ratio 8.30

Quick Ratio 8.30

Debt / Equity Ratio 0.14

Debt / EBITDA -0.50

Debt / FCF -0.44

OCF / Debt -2.21

Interest Coverage -304.16

Altman Z-Score 8.67

Piotroski F-Score 0

Margins & Profitability

Gross Profit Margin 86.2%

Operating Profit Margin -1002.6%

EBITDA Margin -750.9%

Net Profit Margin -765.3%

FCF Margin -1056.6%

Adj. FCF Margin -1117.5%

SBC / Revenue 58.0%

SBC Impact (per share) -5.8%

Returns

Return on Assets -32.3%

Return on Equity -153.1%

Return on Invested Capital -37.8%

Return on Capital Employed -38.8%

Return on Tangible Assets -32.3%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 2

EPS Growth Next 3Y -60.4%

Revenue Growth Next 3Y 18.4%

Earnings Date Nov 5, 2026

EPS Estimate (next Q) -$0.51

EPS Growth Est (next Q) N/A

Revenue Est (next Q) $7.75M

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $26.00

Price Target Upside 79.8%

Cash Flow

Operating Cash Flow $-138.33M

Free Cash Flow $-143.05M

Adj. Free Cash Flow $-151.28M

FCF Per Share -$1.50

OCF Per Share -$1.46

OCF/S Ratio -790.5%

Income Statement

Revenue $13.54M

Gross Profit $10.27M

Operating Income $-135.73M

EBITDA $-124.66M

Net Income $-128.7M

EPS (Diluted) -$1.06

Revenue / Employee $43.39K

Profit / Employee $-412.5K

Employees 312